What this study is
SNAP ON II is a two-arm, parallel-group, multi-center, randomized trial for patients diagnosed with cancer who are planning to undergo expected uncomplicated surgical intervention for their cancer. The study seeks to test whether a mobile app (developed by PistevoDecision) that identifies and connects patients to resources to meet their basic needs (e.g., housing, food, transportation, etc) ccan improve patient outcomes. Prior to their scheduled surgery, patients will download a mobile/web app that asks about their social needs. Then, the treatment group will be connected to community-based resources through FindHelp and the control group will receive access to the Centers for Disease Control tool called Lets Talk: Sharing Info About Your Family Cancer Risk.
What's being tested
- Carealth Phone App
Intervention · DEVICE
The goal for this study is to assess Carealth app's ability to connect patients to resources to meet patient's identified SDH needs, with the end goal of assessing reduction in 30-day readmission and missed visits by connecting patients to resources to meet their social needs in a way that enables them to receive care earlier or avoid complications.
- Let's Talk: Sharing information about Family Cancer Risk
Intervention · BEHAVIORAL
An interactive tool that patients can use to learn about how to talk with their family members about the family member's cancer risk
Study details
- Sponsor
- JHSPH Center for Clinical Trials
- Conditions
- Cancer · Social Support (Formal and Informal) · Mobile Application
- Enrolling
- 722 people
- Starts
- 2024-10-01
- Est. completion
- 2025-08-31
- Design
- Single-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- 18 years or older
- ECOG Performance Status11 score of 2 or less
- Diagnosed with cancer (e.g., head and neck; lung; breast; genitourinary; pancreatic; gastrointestinal; gynecological)
- Requires surgery, with an overnight stay in the hospital, as part of the treatment for their cancer.
- Surgery is considered low risk of major complication, as determined by the surgeon.
- Must be in one of the following categories: 1) have no evidence or suspicion of metastatic disease at time of consult, 2) metastatic in first-line treatment, or 3) metastatic with a 6-month or greater survival expectancy
- Not scheduled for surgery within 2 weeks
- Able to read and respond in English
- Have access to a smartphone, tablet, computer, or other device with an internet connection and web browser, ability and willingness to download the Carealth app
- Able to provide consent to the study
You can't join if
- Diagnosis of cancers in the central nervous system, as these patients may experience cognitive function changes pre- or post-diagnosis that might influence their ability to use the app
- Diagnosis of cancers of the upper extremities, as they may experience limited physical function that may make it challenging to use a mobile app
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 openJohns Hopkins University
Baltimore, Maryland, United States
Northwell Health Cancer Institute
Lake Success, New York, United States
The University of Tennessee Health Science Center
Memphis, Tennessee, United States
Study team
Sponsor
JHSPH Center for Clinical Trials
Study ID IRB00422975
Principal investigator
Lorraine Dean, ScD
Johns Hopkins University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.